细针穿刺诊断转移性前列腺癌的细胞病理与生物标志物评估
该研究回顾2014年1月至2021年6月经细针穿刺诊断的转移性前列腺癌病例,进行细胞形态学与免疫组化生物标志物评估。侵袭性变异常见于既往ADT患者,识别这些变化可提供预后信息并影响治疗决策。
要点
- 既往ADT患者的转移性前列腺癌常出现侵袭性细胞形态变异。
- 非经典型形态与增殖增加可提供重要预后信息。
- PDL1和ARv7等可操作生物标志物可通过免疫组化评估。
核心结论
- 既往ADT患者中常见侵袭性细胞形态变异,识别非经典型形态和增殖增加可提供预后信息并影响治疗决策。
主要发现
- 4例中间型包括2例鳞状分化、2例增殖活跃特征;2例高级别神经内分泌癌具有典型小细胞癌细胞形态。
- PDL1表达见于2例,ARv7表达见于3例。
临床怎么用
- 对既往ADT患者的细针穿刺标本应仔细评估细胞形态,识别非经典型变异和增殖增加。
- 可通过免疫组化评估PDL1和ARv7等临床可操作生物标志物以辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The diagnosis of metastatic prostatic cancer (MPC) by fine needle aspiration (FNA) can usually be rendered by typical cytomorphologic and immunohistochemical (IHC) features. However, MPC diagnosis may be complicated by transformation to atypical phenotypes such as small cell carcinoma, typically under pressure from androgen deprivation therapy (ADT). Predictive and prognostic biomarkers can also be assessed by IHC. This study illustrates how careful assessment of cytologic and biomarker features may provide therapeutic and prognostic information in MPC. DESIGN: We reviewed our anatomic pathology archives for MPC diagnosed by FNA from January 2014 to June 2021. Clinical histories, cytology slides, and cell blocks were reviewed. Extensive IHC biomarker workup was performed, including markers of prostate lineage, cell-cycle dysfunction, Ki-67, neuroendocrine markers, PDL1, and androgen receptor splice variant 7. Cases were reclassified into three categories: conventional type, intermediary type, and high-grade neuroendocrine carcinoma (HGNC). RESULTS: Eighteen patients were identified. Twelve had conventional MPC, including six of six ADT-naive patients. Six of twelve (50%) with prior ADT were reclassified as intermediary or HGNC. Four intermediary cases included two with squamous differentiation and two with pro-proliferative features. Two HGNC cases had typical small cell carcinoma cytomorphology. Expression of PDL1 was identified in two cases and ARv7 in three cases. Five of five intermediary and HGNC patients died of disease versus six of eleven with with conventional type. CONCLUSIONS: Aggressive cytomorphologic variants were commonly identified in patients with prior ADT. Identification of nonconventional cytomorphology and increased proliferation can provide important prognostic information. Recognition of these changes is important for an accurate diagnosis, and the identification of high-grade variants can affect therapeutic decision-making. Clinically actionable biomarkers such as PDL1 and ARv7 can be assessed by IHC.
引用
- Cantley RL, Wang X, Reichert ZR, et al. Metastatic prostate cancer diagnosed by fine-needle aspiration: Contemporary cytopathologic and biomarker assessment with clinical correlates. Cancer Cytopathol. 2022. PMID: 36264673. doi:10.1002/cncy.22652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。